Price (delayed)
$85.69
Market cap
$3.15B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.54
Enterprise value
$3.22B
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.
There are no recent dividends present for RETA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.